CHI Advisors’s Pliant Therapeutics PLRX Stock Holding History

CHI Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$52.3M	Sell	3,014,199 -102,818	-3%	-$1.78M	20.72%	1
2023 Q2	$56.5M	Buy	3,117,017 +115,182	+4%	+$2.73M	17.14%	1
2023 Q1	$79.8M	Sell	3,001,835 -168,057	-5%	-$4.78M	21.2%	2
2022 Q4	$61.3M	Sell	3,169,892 -239,866	-7%	-$5.01M	16.32%	2
2022 Q3	$71.2M	Buy	3,409,758 +302,951	+10%	+$5.8M	19.15%	2
2022 Q2	$24.9M	Buy	3,106,807 +449,350	+17%	+$2.88M	9.5%	4
2022 Q1	$18.6M	Buy	2,657,457 +87,978	+3%	+$898K	7.92%	4
2021 Q4	$34.7M	Buy	2,569,479 +84,755	+3%	+$1.35M	11.51%	4
2021 Q3	$41.9M	Buy	2,484,724 +116,836	+5%	+$2.48M	12.24%	4
2021 Q2	$69M	Buy	2,367,888 +43,093	+2%	+$1.34M	16.04%	3
2021 Q1	$91.4M	Sell	2,324,795 -30,004	-1%	-$974K	18.3%	2
2020 Q4	$53.5M	Buy	2,354,799 +2,508	+0.1%	+$62.9K	15.07%	3
2020 Q3	$53.3M	Buy	2,352,291 +46,297	+2%	+$1.16M	18.95%	2
2020 Q2	$74.9M	Buy	+2,305,994	New	+$61.2M	29.21%	2

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CHI Advisors's PLRX Position: Q3 2023 in Review

CHI Advisors reduced its Pliant Therapeutics (PLRX) stake by 3.3% in Q3 2023, selling an estimated $1.78M and leaving 3,014,199 shares worth $52.3M. The position accounts for 20.72% of the portfolio, ranked #1.

CHI Advisors first reported a position in PLRX in Q2 2020 and has held it in 14 quarters since. The position peaked at $91.4M in Q1 2021. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

CHI Advisors held 3,014,199 shares of Pliant Therapeutics worth $52.3M as of Q3 2023.
CHI Advisors sold 102,818 Pliant Therapeutics shares in Q3 2023, an estimated $1.78M.
Pliant Therapeutics made up 20.72% of CHI Advisors's portfolio in Q3 2023, its #1 holding.
CHI Advisors first reported a position in Pliant Therapeutics in Q2 2020 and has held it in 14 quarters since.
CHI Advisors's Pliant Therapeutics position peaked at $91.4M in Q1 2021.
136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.